Screening for depression among youth with HIV in an integrated care setting

AIDS Care. 2017 Jul;29(7):851-857. doi: 10.1080/09540121.2017.1281878. Epub 2017 Feb 13.

Abstract

Youth living with HIV (YLWH) are at risk for depression. Depressive symptoms can impact treatment engagement, health outcomes, and quality of life. Early identification of symptoms can guide treatment planning. This study aimed to identify trends in depressive symptoms for YLWH in a specialty-care clinic and follow-up clinical treatment procedures. An archival review of a clinical database provided depression screening information for a sample of 130 YLWH between 11 and 25 years old in the southeastern United States. Findings indicated that approximately 24% of the sample screened positive for depression-risk. Most commonly endorsed symptoms included fatigue (54.3%) and sleep difficulties (48.5%). Depressive symptoms did not differ significantly by age, gender, race, ethnicity, or sexual orientation. Youth who acquired HIV behaviorally were more likely to endorse the critical item (i.e., self-harm and/or suicidal ideation) than youth who acquired HIV perinatally. Forty-percent of the sample (i.e., 51 youth) had a follow-up treatment plan. YLWH who endorsed the critical item were more likely to receive follow-up action when compared to those who did not endorse the item. Despite limitations of the study, findings have important implications for clinical care and future research.

Keywords: HIV; Youth; depression; mental health; screening.

MeSH terms

  • Adolescent
  • Adult
  • Anti-HIV Agents / therapeutic use
  • Child
  • Depression / diagnosis*
  • Depression / epidemiology
  • Depression / psychology
  • Female
  • HIV Infections / complications
  • HIV Infections / drug therapy
  • HIV Infections / psychology*
  • Humans
  • Male
  • Mass Screening / methods*
  • Quality of Life
  • Southeastern United States / epidemiology
  • Stress, Psychological / complications
  • Stress, Psychological / epidemiology*
  • Young Adult

Substances

  • Anti-HIV Agents